These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

568 related items for PubMed ID: 10872645

  • 1. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
    Zylber-Katz E, Gomori JM, Schwartz A, Lossos A, Bokstein F, Siegal T.
    Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
    Shapiro WR, Voorhies RM, Hiesiger EM, Sher PB, Basler GA, Lipschutz LE.
    Cancer Res; 1988 Feb 01; 48(3):694-701. PubMed ID: 3335031
    [Abstract] [Full Text] [Related]

  • 3. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
    Lin XB, Zhou NN, Li S, Cai QQ, Xia ZJ, Liao H, Gao Y, Huang HQ.
    Ai Zheng; 2008 Oct 01; 27(10):1100-5. PubMed ID: 18851792
    [Abstract] [Full Text] [Related]

  • 4. Perioperative complications of blood brain barrier disruption under general anesthesia: a retrospective review.
    Elkassabany NM, Bhatia J, Deogaonkar A, Barnett GH, Lotto M, Maurtua M, Ebrahim Z, Schubert A, Ference S, Farag E.
    J Neurosurg Anesthesiol; 2008 Jan 01; 20(1):45-8. PubMed ID: 18157025
    [Abstract] [Full Text] [Related]

  • 5. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
    Fortin D, Desjardins A, Benko A, Niyonsega T, Boudrias M.
    Cancer; 2005 Jun 15; 103(12):2606-15. PubMed ID: 15880378
    [Abstract] [Full Text] [Related]

  • 6. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
    Fortin D, Gendron C, Boudrias M, Garant MP.
    Cancer; 2007 Feb 15; 109(4):751-60. PubMed ID: 17211866
    [Abstract] [Full Text] [Related]

  • 7. Blood-brain barrier disruption and methotrexate in the treatment of a readily transplantable intracerebral osteogenic sarcoma of rats.
    Cosolo W, Christophidis N.
    Cancer Res; 1987 Dec 01; 47(23):6225-8. PubMed ID: 3119195
    [Abstract] [Full Text] [Related]

  • 8. Osmotic blood-brain barrier disruption: pharmacodynamic studies in dogs and a clinical phase I trial in patients with malignant brain tumors.
    Neuwelt EA, Hill SA, Frenkel EP, Diehl JT, Maravilla KR, Vu LH, Clark WK, Rapoport SI, Barnett PA, Lewis SE, Ehle AL, Beyer CW.
    Cancer Treat Rep; 1981 Dec 01; 65 Suppl 2():39-43. PubMed ID: 6809316
    [Abstract] [Full Text] [Related]

  • 9. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
    Jönsson P, Höglund P, Wiebe T, Schrøder H, Seidel H, Skärby T.
    Anticancer Drugs; 2007 Sep 01; 18(8):941-8. PubMed ID: 17667600
    [Abstract] [Full Text] [Related]

  • 10. [Intra-arterial infusion of high dose methotrexate therapy in recurrent gliomas].
    Hayashi A, Kyuma Y.
    Gan To Kagaku Ryoho; 1990 Aug 01; 17(8 Pt 1):1461-6. PubMed ID: 2117886
    [Abstract] [Full Text] [Related]

  • 11. Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
    Galor A, Ference SJ, Singh AD, Lee MS, Stevens GH, Perez VL, Peereboom DM.
    Am J Ophthalmol; 2007 Jul 01; 144(1):45-49. PubMed ID: 17601426
    [Abstract] [Full Text] [Related]

  • 12. [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
    Yamada K, Takahama H, Nakai O, Takanashi T, Hosoya T.
    Gan To Kagaku Ryoho; 1989 Aug 01; 16(8 Pt 2):2692-6. PubMed ID: 2506817
    [Abstract] [Full Text] [Related]

  • 13. Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma.
    Xue H, Wang H, Kong L, Zhou H.
    Chin Med J (Engl); 1998 Aug 01; 111(8):751-3. PubMed ID: 11245034
    [Abstract] [Full Text] [Related]

  • 14. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT.
    Anticancer Drugs; 2013 Feb 01; 24(2):189-97. PubMed ID: 23187460
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles.
    Gao K, Jiang X.
    Int J Pharm; 2006 Mar 09; 310(1-2):213-9. PubMed ID: 16426779
    [Abstract] [Full Text] [Related]

  • 18. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
    McAllister LD, Doolittle ND, Guastadisegni PE, Kraemer DF, Lacy CA, Crossen JR, Neuwelt EA.
    Neurosurgery; 2000 Jan 09; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
    [Abstract] [Full Text] [Related]

  • 19. [Effect of Chai-ling-tang (Sairei-to) for methotrexate concentration degradation delay by methotrexate high-dose therapy].
    Utsuki S, Oka H, Suzuki S, Sato S, Osawa S, Koizumi H, Miyajima Y, Fujii K.
    No Shinkei Geka; 2010 Feb 09; 38(2):133-7. PubMed ID: 20166525
    [Abstract] [Full Text] [Related]

  • 20. CXCL13 and CXCL12 in central nervous system lymphoma patients.
    Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, Widmann T, Thiel E.
    Clin Cancer Res; 2009 Oct 01; 15(19):5968-73. PubMed ID: 19773382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.